Rheumatoid Arthritis Management

Introduction to Methotrexate Tapering

When tapering methotrexate in patients with rheumatoid arthritis, gradual dose reduction is conditionally recommended over abrupt discontinuation, and patients should be at target (low disease activity or remission) for at least 6 months before considering any tapering, as recommended by the American College of Rheumatology 1, 2

Glucocorticoids should be tapered and discontinued first, as suggested by the European League Against Rheumatism 3
If on combination therapy with biologics, consider tapering biologics before methotrexate, as recommended by the European League Against Rheumatism 3

The first option is to continue methotrexate at the current dose if possible, as recommended by the American College of Rheumatology 1, 2
If tapering is desired, implement gradual dose reduction rather than discontinuation, according to the American College of Rheumatology 1, 2
If discontinuation is necessary, use gradual tapering rather than abrupt cessation, as recommended by the American College of Rheumatology 1, 2

If on methotrexate plus biologic/tsDMARD, methotrexate should be gradually discontinued before the biologic/tsDMARD if discontinuation is desired, as recommended by the American College of Rheumatology 1, 2
For triple therapy, consider discontinuing sulfasalazine before hydroxychloroquine, according to the American College of Rheumatology 1, 2

In patients with subcutaneous nodules, consider switching to non-methotrexate DMARD if nodules are progressive, as recommended by the American College of Rheumatology 1, 2
For patients with mild, stable lung disease, methotrexate can generally be continued with appropriate monitoring, according to the American College of Rheumatology 1, 2
Complete discontinuation of all DMARDs has a high risk of flare (up to 67% in some studies), as reported by the European League Against Rheumatism 3

Tapering carries approximately a 10% reduction in the ability to sustain remission, although the exact figure is not provided in the given references, it is implied that tapering has some risk 3
Radiographic progression may occur even with clinical remission, requiring careful monitoring, as suggested by the European League Against Rheumatism 3
Methotrexate is suitable for long-term use beyond 1 year in patients with rheumatoid arthritis who have achieved low disease activity or remission, and should be continued at the current effective dose 4
The American College of Rheumatology recommends ongoing monitoring for patients on methotrexate for 1 year or more, including laboratory tests every 1-3 months and clinical assessment for side effects and risk factors at each visit 4

Methotrexate can be used as the anchor for combination therapy when monotherapy does not achieve disease control, as recommended by the American College of Rheumatology 4
The American College of Rheumatology recommends initiating methotrexate orally at 10-15 mg/week, with escalation of 5 mg every 2-4 weeks up to 20-30 mg/week, depending on clinical response and tolerability, and at least 5 mg folic acid supplementation weekly 4
Pre-treatment evaluation should include complete blood count, liver function tests, serum creatinine with creatinine clearance calculation, chest X-ray, and consideration of hepatitis B/C serology, HIV testing, fasting glucose, lipid profile, and pregnancy test, as recommended by the American College of Rheumatology 4
The monitoring schedule should include every 1-1.5 months until a stable dose is reached, and every 1-3 months thereafter, with clinical assessment for side effects at each visit, according to the American College of Rheumatology 4

Long-term methotrexate use has demonstrated reduced mortality risk compared to RA patients not on methotrexate, with a hazard ratio of 0.3 for cardiovascular mortality 4
Liver toxicity requires stopping methotrexate if ALT/AST increases to >3x upper limit of normal, with possible reinstitution at a lower dose after normalization 4
Pulmonary toxicity can generally be managed with continued methotrexate use and appropriate monitoring for patients with mild/stable lung disease 2
Methotrexate should be discontinued at least 3 months before planned pregnancy for both men and women, and should not be used during pregnancy or breastfeeding 4

Methotrexate is conditionally recommended over alternative DMARDs for patients with clinically diagnosed mild and stable airway or parenchymal lung disease who have moderate-to-high disease activity, as recommended by the American College of Rheumatology 1
Methotrexate is conditionally recommended over alternative DMARDs for patients with subcutaneous nodules who have moderate-to-high disease activity, according to the American College of Rheumatology 1
In DMARD-naive patients, methotrexate monotherapy is conditionally recommended over combination with biologic DMARDs or targeted synthetic DMARDs, as recommended by the American College of Rheumatology 2
For patients taking maximally tolerated doses of methotrexate who are not at target, addition of a biologic DMARD or targeted synthetic DMARD is conditionally recommended over triple therapy, as suggested by the American College of Rheumatology 2